CYNTHIA RICE c Senior Vice President, Advocacy & Policy JDRF - - PowerPoint PPT Presentation

▶
cynthia rice
SMART_READER_LITE
LIVE PREVIEW

CYNTHIA RICE c Senior Vice President, Advocacy & Policy JDRF - - PowerPoint PPT Presentation

Aug 03, 2023 362 likes •496 views

CYNTHIA RICE c Senior Vice President, Advocacy & Policy JDRF JDRF ADVOCACY UPDATE Presented by: Cynthia Rice, SVP, Advocacy & Policy, JDRF - crice@jdrf.org March 5, 2016 JDRFS MISSION JDRFs Vision and Mission A world without

slide-1
SLIDE 1

CYNTHIA RICE

c

Senior Vice President, Advocacy & Policy JDRF

slide-2
SLIDE 2

March 5, 2016

JDRF ADVOCACY UPDATE

Presented by: Cynthia Rice, SVP, Advocacy & Policy, JDRF - crice@jdrf.org

slide-3
SLIDE 3

3

JDRF’s Vision and Mission

JDRF’S MISSION

VIS ISION

A world without type 1 diabetes

MIS ISSION

Accelerating life- changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications

slide-4
SLIDE 4

4

JDRF Advances Life-Changing Breakthroughs Through both Research and Advocacy

ADVOCACY

  • JDRF invested nearly $2 billion in research since 1970
  • Leverages resources from governments, other

foundations

  • Influences policy and commercial landscape to

accelerate therapies

slide-5
SLIDE 5

JDRF’s Volunteers: A Force on Capitol Hill

ADVOCACY

slide-6
SLIDE 6

30 30 30 30 30 70 70 100 150 150 150 150 150 150 150 150 150 150 150 150 150 150

1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Public Law 105-33 Public Law 106-554 Public law 107-360 Public Law 110-173 Public Law 110-275 Public Law 111-309 Public Law 112-240 Public Law 113-932 Public Law 114-10

6

ADVOCACY

JDRF Success: Nearly $2.5 Billion T1D Research Funding through Special Diabetes Program

slide-7
SLIDE 7

7

JDRF Priority: Regulatory Pathways

REGULATORY AGENCIES JDRF IMPACT OUTCOME

  • Safe and effective new therapies

available to people with T1D in reasonable time period

  • Decide what clinical research can be

carried out

  • Approve new therapies for people with

T1D

  • Inform decisions, policies that affect T1D
  • Help shape regulatory pathways
  • Address knowledge gaps

ADVOCACY

slide-8
SLIDE 8

8

JDRF Success: Artificial Pancreas FDA Pathway

ADVOCACY

  • JDRF led process to define FDA pathway

for artificial pancreas studies and product review

  • Final guidance issued which reflected

JDRF goals and clinical recommendations

  • As results, new systems and components

have been approved and are in development

slide-9
SLIDE 9

9

JDRF Priority: Health Policy

PAYERS JDRF ROLE OUTCOME

  • Timely access to safe, effective, and

affordable new therapies for people with T1D

  • Decide what therapies are covered and at

what cost to the individual

  • Inform decisions and policies that affect T1D
  • Help shape reimbursement landscape
  • Address knowledge gaps

ADVOCACY

slide-10
SLIDE 10

JDRF Funded Trial to Demonstrate CGM Effectiveness Major Diabetes Clinical Guidelines Include CGM Majority of Private Health Plans Cover CGM for T1D

10

JDRF Success: CGM Campaign Achieved Clinical Guidelines and Health Plan Coverage

ADVOCACY “The most important milestone towards getting broad reimbursement for CGM is the …randomized, 450-patient CGM trial by the Juvenile Diabetes Research Foundation.”

slide-11
SLIDE 11

Action Needed

HEALTH POLICY

  • Continuous glucose monitors
  • Recommended by clinical guidelines
  • Covered by nearly all private plans
  • Medicare lags behind
  • “Medicare CGM Access Act of 2015”
  • CGM Medicare coverage + pathway

for artificial pancreas systems

  • S. 804 & H.R. 1427
  • As your members of Congress to co-

sponsor at www.jdrf.org/cgm

  • Sign up to be an advocate!
  • Text “Act” to 53731 or
  • Visit booth in lobby or
  • Go to www.jdrf.org/advocacy
  • Tell us who you know
  • Congress
  • FDA/CMS/health plans

11

ADVOCACY